1227067-61-9 Usage
General Description
The chemical "1-(4-(3-(4-(1H-benzo[d]imidazole-2-carbonyl)phenoxy)pyrazin-2-yl)piperidin-1-yl)ethanone" is a compound with a complex structure that includes a piperidine ring, pyrazine ring, and a benzo[d]imidazole-2-carbonyl group. It is also known as E7046 and is a potent and selective antagonist of the chemokine receptor CCR8. 1-(4-(3-(4-(1H-benzo[d]imidazole-2-carbonyl)phenoxy)pyrazin-2-yl)piperidin-1-yl)ethanone has shown potential in the treatment of inflammatory and autoimmune diseases by blocking the migration of certain immune cells to sites of inflammation. Additionally, it has been studied for its potential in the treatment of certain types of cancer and has shown promising results in preclinical studies. The complex structure of this chemical makes it a subject of interest for further research and development in the field of pharmaceuticals.
Check Digit Verification of cas no
The CAS Registry Mumber 1227067-61-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,7,0,6 and 7 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1227067-61:
(9*1)+(8*2)+(7*2)+(6*7)+(5*0)+(4*6)+(3*7)+(2*6)+(1*1)=139
139 % 10 = 9
So 1227067-61-9 is a valid CAS Registry Number.
1227067-61-9Relevant articles and documents
Discovery of clinical candidate 1-(4-(3-(4-(1 H-benzo[ d ]imidazole-2-carbonyl)phenoxy)pyrazin-2-yl)piperidin-1-yl)ethanone (AMG 579), A potent, selective, and efficacious inhibitor of phosphodiesterase 10A (PDE10A)
Hu, Essa,Chen, Ning,Bourbeau, Matthew P.,Harrington, Paul E.,Biswas, Kaustav,Kunz, Roxanne K.,Andrews, Kristin L.,Chmait, Samer,Zhao, Xiaoning,Davis, Carl,Ma, Ji,Shi, Jianxia,Lester-Zeiner, Dianna,Danao, Jean,Able, Jessica,Cueva, Madelyn,Talreja, Santosh,Kornecook, Thomas,Chen, Hang,Porter, Amy,Hungate, Randall,Treanor, James,Allen, Jennifer R.
, p. 6632 - 6641 (2014/10/15)
We report the identification of a PDE10A clinical candidate by optimizing potency and in vivo efficacy of promising keto-benzimidazole leads 1 and 2. Significant increase in biochemical potency was observed when the saturated rings on morpholine 1 and N-a
